Background {#Sec1}
==========

Chronic heart failure (CHF) is one of the most frequently diagnosed diseases causing disability and death in the Western hemisphere. It is characterized by a prevalence that increases with age \[[@CR1]\]. In Germany, heart failure is the most common reason for hospitalization with about 396,000 cases in 2013 \[[@CR2]\]. Direct medical costs related to heart failure account for 1--2 % of total health care expenditure \[[@CR3]\].

In the majority of cases, home telemonitoring solutions in health care delivery to patients with CHF show advantages over usual care in terms of clinical outcomes. Several meta-analyses reveal that total mortality and number of hospitalizations tend to decrease, while patients' quality of life improves \[[@CR4]--[@CR6]\]. Two subsequently published trials (Telemedical Interventional Management in Heart Failure trial (TIM-HF) \[[@CR7]\], Telemonitoring in patients with Heart Failure trial (TELE-HF) \[[@CR8]\]) show neutral findings in general. However, the health economic impact has not been clearly demonstrated so far \[[@CR9]\]. A meta-analysis by Klersy et al. (2011) states that the difference in costs between remote patient monitoring and usual care ranges from Euro300 to Euro1000, favoring remote patient monitoring because of a lower hospitalization rate. Thus, direct costs for hospitalization were approximated by diagnosis-related group tariffs \[[@CR10]\]. A more detailed evaluation of efficiency and economic feasibility could help to determine cost-effectiveness and to avoid misallocation of resources \[[@CR11]\].

The CardioBBEAT trial was designed to assess the health economic impact of a dedicated home telemonitoring system for patients with CHF based on actual costs directly obtained from patients' health care providers. The present report provides details on the outline of the study and an analysis of the study population's baseline data.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

CardioBBEAT represents a randomized, controlled, open, multicenter trial with two prospective study arms. Patients were recruited at ten study sites from five areas of varying economic status in Germany: namely, Berlin, Brandenburg, Bavaria, Hamburg and North Rhine-Westphalia. This diversity allows for investigating the impact of regional differences in medical care, with general medical care predominating in rural districts compared to predominantly specialist care in urban areas. Each site was responsible for recruiting as well as following-up on their patients. Specified information about inclusion and exclusion criteria is displayed in Table [1](#Tab1){ref-type="table"}.Table 1Summary of inclusion and exclusion criteria at screeningInclusion criteria  Confirmed diagnosis of CHF based on ESC guidelines  Symptoms corresponding to NYHA functional class II--IV  AHA classification stages C--D  LVEF ≤ 40 %  Age ≥ 18 years  Patient is discharged after being hospitalized for CHF within the last 12 months  Patient is able to understand the German language  Patient has sufficient eyesight to understand and follow the instructions communicated by Motiva®  Patient is willing and able to use the required hardware and software and to maintain a patient diary  Patient is residing within geographical reach of one of the ten telemonitoring centers in order to receive additional treatment if required as well as follow-up consultation  Patient gives informed consent regarding benefits and risks related to the trial, and to sign a participation agreement for the installation of the home telemonitoring system Motiva®Exclusion criteria  Myocardial infarction within the past 4 weeks  Heart surgery or any coronary intervention within the past 8 weeks  Cardiogenic shock within the past 4 weeks  Intended cardiac surgery within the next 6 months or priority status on a waiting list for organ transplantation  Severe chronic and pulmonary illness with an immediate impact on the main outcome measures  Renal dysfunction requiring dialysis  Dementia or other severe cognitive impairment  Psychiatric disorders prohibiting a participation in the trial  Patient is discharged to or living in an older persons clinic or a nursing home  Patient is participating in another clinical trial*AHA* American Heart Association, staging of heart failure, *CHF* chronic heart failure, *ESC* European Society of Cardiology, *LVEF* left ventricular ejection fraction *NYHA* New York Heart Association, classification of heart failure

The study has been conducted in accordance with the principles stated in the Declaration of Helsinki, the Good Clinical Practice (International Conference on Harmonization), and national as well as local regulations. The research protocol was approved by the responsible ethics committees (Table [2](#Tab2){ref-type="table"}), and written informed consent was obtained from all patients prior to any study-related procedures. The study is monitored by an independent external institute to ensure that every participating site abides by the study protocol and to perform external quality control of the data.Table 2List of ethical bodiesEthical bodyReference numberEthik-Kommission für Forschungsfragen der Universität BayreuthO 1305 -- HB/IDLandesärztekammer Brandenburg, Ethik-KommissionAS 94(a)/2009Ethikkommission -- Ethikausschuss 2 am Campus Virchow-Klinikum BerlinEA2/084/09Ethik-Kommission für Forschungsfragen der Universität BayreuthO 1305 -- HB/IDEthik-Kommission für Forschungsfragen der Universität BayreuthO 1305 -- HB/IDMedizinische Fakultät der Universität Duisburg-Essen, Ethik-Kommission10-4536Ethik-Kommission der Bayerischen Landesärztekammer7/11014Universität Würzburg, Ethik-Kommission bei der Medizinischen Fakultät128/11Ethik-Kommission der Ärztekammer HamburgMC-141/11Ethik-Kommission für Forschungsfragen der Universität BayreuthO 1305 -- GBÄrztekammer Nordrhein, Ethikkommission2012451

Setting {#Sec4}
-------

During the trial, all patients receive best medical treatment according to the current guidelines of the European Society of Cardiology (ESC) \[[@CR12], [@CR13]\].

Patients in the control group only receive best medical treatment as stated above, whereas patients in the intervention group additionally receive home telemonitoring-supported care that connects them to the participating care providers by individual guideline-compliant care plans using the telemedicine-system Motiva® (Philips Medical Systems GmbH, Hamburg, Germany).

Motiva® is an interactive bi-directional home telemonitoring system that provides remote monitoring, empowers patients to manage their disease state more effectively and enables physicians to keep in contact with the patient at home on a daily basis. Patients measure their vital signs (blood pressure, heart rate, and weight) every day and Motiva® transfers the data to the relevant telemonitoring center. In doing so, signals of decompensation regarding their heart function can be detected at an early stage and counteractive measures can be taken. In addition, patients receive information via Motiva®, i.e. coaching material, evaluations, reminders, and feedback regarding their health status as well as references to potentially necessary CHF treatment adaptations. If questionnaires reveal any problems, patients receive a phone call from the study site. Additionally, patients receive standardized questionnaires related to symptoms of cardiac decompensation, hypotension or hypertension or abnormal pulse rates. A call from the telemedicine center is made if patients gain more than 2 kg within 3 days, if their systolic blood pressure exceeds 140 mmHg or is lower than 90 mmHg, or their resting heart rate exceeds 80 bpm or is lower than 50 bpm.

A secured broadband connection (Digital Subscriber Line (DSL) or Universal Mobile Telecommunications System (UMTS)) and a set-top box turn the patient's television into their center of personalized care protected by a patient-specific password. Thus, patients can transfer all information about their health status to their attending physician safely.

Motiva® is been provided by Philips Medical Systems GmbH, Hamburg, Germany. The telecommunication infrastructure to transfer patients' data is made available by T-Systems International GmbH, Frankfurt, Germany. Both are provided without any obligations that could influence the study.

Randomization {#Sec5}
-------------

To assign patients to one of the two study arms, CardioBBEAT used a centralized stacked randomization technique. Patients at home who were managed in cardiologic practices were randomized patient-individually. Patients primarily managed by their general practitioner (GP), on the other hand, were cluster-randomized by their GP's medical practices, to minimize carry-over effects and to keep the organizational effort manageable. The results of the randomization process with regard to the patients were displayed via the study's electronic Case Report Form (eCRF) directly after inclusion into the trial. The study center in charge did inform the patients' attending physicians whether their respective patients were enrolled in the trial and to which study arm they were assigned.

Treatment patterns {#Sec6}
------------------

After patients are discharged from inpatient care, their GPs or outpatient medical specialists will provide their ambulatory care. These physicians have access to individual patient care plans and are authorized to complete or modify them.

Subjects enrolled in the control group receive best medical treatment according to the current guidelines of the European Society of Cardiology (ESC). Subjects enrolled in the intervention group are additionally supported by the telemedicine system Motiva® installed at the patients' home usually within 2 weeks.

All trial participants maintain a patient diary and are urged to document any health disturbances at least once a week, such as hospitalizations (date of hospitalization, reason for admission, and length of stay), consultations by any physician, and change in medication or dose rate as well as adverse effects. In addition, every patient has to participate in 3 trial-specific examinations (Table [3](#Tab3){ref-type="table"}) at their relevant study site, that take place at the time of enrollment and after 6 as well as 12 months.Table 3Trial-specific examinationsEnrollment examination1. Patient briefing2. Written informed consent3. Verification of inclusion and exclusion criteria4. Demography  Sex  Date of birth  Marital status  Size and weight5. Hemodynamic parameters  Heart rate  Blood pressure (systolic/diastolic)6. Disease-related parameters  Medical history  CHF (date of diagnosis, aetiology, inpatient treatments, NYHA classification, AHA stadium)  Comorbidities  Medication  Care plan compilation  6 MWD7. Health-related quality of life assessment  SF-36v2 (generic quality of life questionnaire)  WHO-5 (generic quality of life questionnaire)  KCCQ (disease-specific quality of life questionnaire)Follow-up and final examination1. Demography  Weight2. Hemodynamic parameters  Heart rate  Blood pressure (systolic/diastolic)3. Disease-related parameters  CHF (NYHA classification, AHA stadium)  Newly occurring comorbidities  Medication  Hospitalizations or admissions to a nursing home  Patient diary monitoring and validation of AE/SAE  6 MWD4. Health-related quality of life assessment  SF-36v2 (generic quality of life questionnaire)  WHO-5 (generic quality of life questionnaire)  KCCQ (disease-specific quality of life questionnaire)In case a patient dies during the trial  Date of death  Cause of death*6 MWD* 6-minute walking distance*, AE* adverse event, *AHA* American Heart Association, staging of heart failure, *ESC* European Society of Cardiology, *KCCQ* Kansas City Cardiomyopathy Questionnaire with 23 items for measuring disease-specific domains in CHF, *LVEF* left ventricular ejection fraction, *NYHA* New York Heart Association, classification of heart failure, *SAE* serious adverse event, *SF-36v2* short form health survey with 36 questions using norm-based scoring, *WHO-5* World Health Organization Five, well-being index

Clinical outcome measures {#Sec7}
-------------------------

The primary outcome measure to assess the benefit of home telemonitoring is the combined clinical endpoint "days alive and not in hospital nor inpatient care per potential days in study." For deceased patients, the loss in lifetime is taken into account by setting the denominator to 360 days, for patients lost to follow-up, time to last contact is used. Secondary outcome measures are total mortality, number of inpatient treatments, length of stay in hospital or nursing home, functional state of health and health-related quality of life. These will be determined by the following parameters: days survived in the study, number of hospitalizations for any reason during the study (especially cardiac and heart failure-related reasons), number of days in hospital or nursing home per study month, generic (short form health survey with 36 questions using norm-based scoring (SF-36v2), World Health Organization Five, well-being index (WHO-5)) and disease-specific (Kansas City Cardiomyopathy Questionnaire, (KCCQ)) health-related quality of life as well as medical condition and capacity of each patient.

CardioBBEAT may also be able to differentiate between particular sub-groups (e.g. gender-specific, NYHA-specific, urban/rural, diabetes mellitus) while analyzing the effectiveness of the intervention. The expectation is that several patient groups can be identified which are particularly suited for home telemonitoring with regard to clinical and/or economic outcome.

Cost data {#Sec8}
---------

CardioBBEAT aims to reflect the impact of home telemonitoring within an actual health care setting based on originally obtained cost data subdivided into cost of intervention, cost of inpatient and outpatient care, rehabilitation, nursing, and life-saving appliances. To this end, cost data are obtained from patients' health insurance companies and later on validated using the records of the telemonitoring centers, GPs and medical specialists as well as patients' diaries. Health insurance data will be obtained similarly for both, patients in the intervention group as well as the control group to avoid ascertainment bias.

All data are analyzed with appropriate statistical methods to determine the economic effectiveness of home telemonitoring for patients with CHF. Common approaches for the analysis of cost data such as *t* tests, analysis of covariance, bootstrap techniques or permutation tests will be compared regarding their feasibility, the validity of underlying assumptions and their stability and robustness in particular if missing values have to be taken into account.

Especially when analyzing cost data or determining the Incremental Cost-Effectiveness Ratio (ICER), assumptions are made regarding discount rate, utilities, projections or estimation of costs, which are based on uncertain hypotheses. To better understand the outcomes of these analyses, CardioBBEAT uses sensitivity analyses considering best-case and worst-case scenarios to demonstrate in which way the outcomes depend on these assumptions and how they affect their assessment.

Statistical analysis {#Sec9}
--------------------

The primary endpoint ICER, consisting of the group's difference in total cost and the combined clinical endpoint "days alive and not in hospital nor inpatient care per potential days in study", is calculated with confidence intervals obtained by resampling methods. The comparative conventional endpoint "event-free survival" to measure the intervention's effectiveness is evaluated using the Kaplan-Meier analysis and log rank tests. To incorporate possible repeated hospitalizations of a patient, additional analyses will be performed, e.g. comparison of quarterly data and recurrent event analysis.

Secondary outcome measures such as number of stays in hospital per quarter, health-related quality of life or time of survival are analyzed via permutation test, covariance analysis or log rank test as part of the Kaplan-Meier analysis.

Furthermore, the trial uses a cluster-randomization technique and, therefore, correlation effects can evolve due to the collective treatment of patients in a cardiology center, medical practice, or by a single study nurse. Such effects can result in incorrect *p* values. CardioBBEAT uses frailty and multi-level models to assess if and where such correlations occur. The magnitude of these correlations will be measured and the *p* values will be rectified.

Since at planning stage neither an established statistical method to directly compare costs and ICERs nor sufficient data to estimate the variability of cost estimates was available, the sample size was determined based on literature data. With respect to clinical endpoints, the figures were rather stable and converged to a minimum of 300 patients per group. Since the primary endpoint was expected to be mainly driven by clinical events, it was assumed that the sample size will also be sufficient for the continuously distributed ICER.

Results {#Sec10}
=======

The study group comprised 621 patients, predominantly men. Four hundred and seventy-two (76 %) patients were treated by 449 GPs and 149 (24 %) were treated in 119 cardiologic practices. Three hundred and two patients were randomized into the intervention group and 319 patients into the control group. Ischemic cardiomyopathy was the leading cause of heart failure (59 %). Although randomly assigned, subjects of the control group were significantly more often in NYHA functional classes III or IV and exhibited peripheral edema or renal dysfunction, respectively, more frequently (Table [4](#Tab4){ref-type="table"}). Additionally, the control and intervention group differed in heart rhythm disturbances (Table [5](#Tab5){ref-type="table"}). No differences were detected regarding risk factor profile, comorbidities, echocardiographic parameters, especially left ventricular and diastolic diameter and ejection fraction, as well as functional test (6 MWD) results, medication and quality of life (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}).Table 4Baseline characteristics of the CardioBBEAT study participantsCharacteristicAll patients *n* = 621Usual care *n* = 319 (51 %)Monitoring *n* = 302 (49 %)*p* valueDemographic profile  Age (years)   mean ± SD63.0 ± 11.563.5 ± 11.462.5 ± 11.60.303   median (IQR)65 (55--72)65 (55--73)64 (54--72)  Male sex, *n* (%)544 (88)280 (88)264 (87)0.990  Living alone, *n* (%)159 (26)77 (24)82 (27)0.442  Education (years) -- number of patients (% valid)607 (98)311 (98)296 (98)   mean ± SD12 ± 312 ± 312 ± 30.803   median (IQR)11 (10--13)11 (10--13)12 (10--13)  Causes of heart failure, *n* (%)0.797   Ischemic CM363 (59)185 (58)178 (59)   Non-ischemic CM258 (42)134 (42)124 (41)  NYHA class, *n* (%)0.086   II430 (69)209 (66)221 (73)   III186 (30)108 (34)78 (26)   IV5 (1)2 (1)3 (1)  NYHA class III--IV, *n* (%)191 (31)110 (35)81 (27)0.048  Peripheral edema, *n* (%)131 (21)83 (26)48 (16)0.003Comorbidities, *n* (%)  Stroke/TIA41 (7)21 (7)20 (7)1.000  PAD56 (9)24 (8)32 (11)0.232  COPD87 (14)48 (15)39 (13)0.516  Sleep apnea45 (7)25 (8)20 (7)0.668  Renal dysfunction (GFR ≤ 60 ml/min)148 (24)87 (27)61 (20)0.048  Depression51 (8)24 (8)27 (9)0.619  Resuscitation81 (13)37 (12)44 (15)0.327Risk factor profile  BMI (kg/m^2^) -- number of patients (% valid)619 (100)318 (100)301 (100)   mean ± SD28 ± 528 ± 528 ± 50.529   median (IQR)28 (25--31)28 (25--32)27 (25--31)  History of smoking -- number/total number (%)435/620 (70)221/319 (69)214/301 (71)0.684  Diabetes mellitus, *n* (%)219 (35)103 (32)116 (38)0.131  Hypertension, *n* (%)533 (86)269 (84)264 (87)0.323*BMI* body mass index*, CM* cardiomyopathy, *COPD* chronic obstructive pulmonary disease, *GFR* glomerular filtration rate, *IQR* interquartile range, *NYHA* New York Heart Association, classification of heart failure, *PAD* peripheral arterial disease, *TIA* transient ischemic attackTable 5Baseline characteristics of the CardioBBEAT study participants **-** DiagnosticCharacteristicAll patients *n* = 621Usual care *n* = 319 (51 %)Monitoring *n* = 302 (49 %)*p* valueECG  Heart rate (1/min) -- number of patients (% valid)616 (99)315 (99)301 (100)   mean ± SD72 ± 1472 ± 1472 ± 130.862   median (IQR)71 (63--81)71 (63--82)71 (62--80)  Heart rhythm -- number/total number (%)0.031   Sinus rhythm379/619 (61)185/318 (58)194/301 (65)   Atrial fibrillation78/619 (13)46/318 (15)32/301 (11)   Pacemaker ECG154/619 (25)86/318 (27)68/301 (23)   Other8/619 (1)1/318 (0)7/301 (2)  Conduction disorder -- number/total number (%)   LBBB145/543 (27)69/272 (25)76/271 (28)0.543   RBBB49/544 (9)28/273 (10)21/271 (8)0.383  QRS duration (ms) -- number of patients (% valid)568 (92)288 (90)280 (93)   mean ± SD123 ± 33125 ± 34121 ± 320.151   median (IQR)110 (100--144)116 (100--150)110 (100--140)2D echocardiography  LVEDD (mm) -- number of patients (% valid)584 (94)297 (93)287 (95)   mean (mm) ± SD62 ± 962 ± 963 ± 90.580   median (IQR)62 (57--68)62 (57--68)62 (57--68)  LVEF (%) -- number of patients (% valid)619 (100)317 (100)302 (100)   mean ± SD30 ± 731 ± 730 ± 80.580   median (IQR)31 (25--37)31 (25--37)30 (25--36)  Mitral insufficiency -- number/total number (%)0.319   none102/614 (17)55/315 (18)47/299 (16)   mild370/614 (60)180/315 (57)190/299 (64)   moderate121/614 (20)70/315 (22)51/299 (17)   severe21/614 (3)10/315 (3)11/299 (4)6-minute walk test -- number of patients (% valid)559 (90)284 (89)275 (91)   mean (m) ± SD375 ± 132376 ± 132374 ± 1310.804   median (IQR)400 (300--458)404 (300--455)400 (300--460)*2D* two-dimensional, *ECG* electrocardiogram, *IQR* interquartile range, *LBBB* left bundle branch block,*LVEDD* left ventricular end-diastolic dimension, *LVEF* left ventricular ejection fraction, *QRS* combination of three of the graphical deflections seen on a typical ECG, *RBBB* right bundle branch blockTable 6Baseline characteristics of the CardioBBEAT study participants **-** TherapyCharacteristicAll patients *n* = 621Usual care *n* = 319 (51 %)Monitoring *n* = 302 (49 %)*p* valueMedication  ACE inhibitor/ARB, *n* (%)577 (93)297 (93)280 (93)0.974  Beta blocker -- number/total number (%)591/620 (95)303/319 (95)288/301 (96)0.826  MR antagonist, *n* (%)439 (71)232 (73)207 (69)0.291  Diuretics, *n* (%)506 (82)255 (80)251 (83)0.360  Glycosides, *n* (%)95 (15)50 (16)45 (15)0.876  Amiodarone, *n* (%)80 (13)48 (15)32 (11)0.125  Anticoagulation, *n* (%)   Vitamin K antagonist231 (37)122 (38)109 (36)0.637   Other42 (7)24 (8)18 (6)0.538Devices, *n* (%)  Pacemaker101 (16)61 (19)40 (13)0.061  ICD0.280   with monitoring63 (10)31 (10)32 (11)   without monitoring242 (39)134 (42)108 (36)  CRT-D89 (14)40 (13)49 (16)0.232*ACE* angiotensin converting enzyme, *ARB* angiotensin receptor blocker, *CRT-D* cardiac resynchronization therapy combined with defibrillation *ICD* implantable cardioverter defibrillator, *MR* mineralocorticoid receptorTable 7Baseline characteristics of the CardioBBEAT study participants -- Quality of lifeCharacteristicAll patients *n* = 621Usual care *n* = 319 (51 %)Monitoring *n* = 302 (49 %)*p* valueSF-36v2  Physical comp. sum -- number of patients (% valid)581 (94)299 (94)282 (93)   mean ± SD39 ± 1039 ± 1038 ± 100.458   median (IQR)38 (32--46)38 (32--46)38 (32--45)  Mental comp. sum -- number of patients (% valid)581 (94)299 (94)282 (93)   mean ± SD45 ± 1345 ± 1244 ± 130.239   median (IQR)46 (35--56)46 (36--55)45 (34--56)  Physical functioning -- number of patients (% valid)591 (95)304 (95)287 (95)   mean ± SD51 ± 2752 ± 2750 ± 270.445   median (IQR)50 (30--75)50 (30--75)50 (30--70)WHO-5  Score -- number of patients (% valid)586 (94)301 (94)285 (94)   mean ± SD55 ± 2555 ± 2554 ± 250.588   median (IQR)56 (36--76)56 (36--76)56 (32--76)KCCQ  Overall sum -- number of patients (% valid)591 (95)305 (96)286 (95)   mean ± SD59 ± 2459 ± 2460 ± 230.574   median (IQR)61 (42--80)60 (42--80)62 (42--80)  Clinical sum -- number of patients (% valid)591 (95)305 (96)286 (95)   mean ± SD63 ± 2563 ± 2664 ± 240.409   median (IQR)67 (45--85)67 (44--85)69 (49--84)*Comp* component, *IQR* interquartile range, *KCCQ* Kansas City cardiomyopathy questionnaire with 23 items for measuring disease-specific domains in CHF, *SF-36v2* short form health survey with 36 questions using norm-based scoring, *sum* summary, *WHO-5* World Health Organization Five, well-being index

In comparison with recently published German trials (TIM-HF \[[@CR7]\], Interdisciplinary Network for Heart failure study (INH) \[[@CR14]\]) the CardioBBEAT target population was slightly younger and comprised more male patients with fewer in NYHA classes III and IV. Nevertheless, all patients were either categorized in AHA stages C or D and every fifth patient of the given cohort was diagnosed with peripheral edema; this suggests that the study population had a comparable degree of heart failure. Regarding comorbidities and risk factor profile, the study population was very similar, particularly for diabetes or renal dysfunction. Remarkably, it revealed a left bundle branch block in approximately 25 % of the population, a rhythm disorder with a known worse prognosis \[[@CR15]\]. Furthermore, detailed information on prognostic relevant therapies was documented. Besides a high proportion of guideline-based pharmacotherapy including beta blockers and ACE inhibitors/ARB inhibitors, the study population was treated with mineralocorticoid receptor blockers in 71 % of all cases. A cardioverter-defibrillator or a resynchronization system was implanted in two thirds of our patients (comparable to TIM-HF study \[[@CR7]\]) with a considerable prognostic impact on primary and secondary endpoints. Table [8](#Tab8){ref-type="table"} compares the most important baseline characteristics with TIM-HF \[[@CR7]\] and INH \[[@CR14]\].Table 8Compared baseline characteristics of the CardioBBEAT, TIM-HF and INH study participantsVariableCardioBBEATTIM-HFINHUsual careMonitoringUsual careMonitoringUsual careMonitoring(*n* = 319)(*n* = 302)(*n* = 356)(*n* = 354)(*n* = 363)(*n* = 352)Demographic profile  Age (years)63.5 ± 11.462.5 ± 11.666.9 ± 10.566.9 ± 10.869.4 ± 11.567.7 ± 12.8  Male sex (%)888782817171  Living alone (%)242722213530Clinical profile  NYHA class (%)   I000023   II657351506254   III342649503140   IV110053Risk factor profile  BMI (kg/m^2^)28 ± 528 ± 528 ± 528 ± 5n.a.n.a.  Diabetes mellitus (%)323839403636  Hypertension (%)848766687772Diagnostic  Heart rate (1/min)72 ± 1472 ± 1371 ± 1371 ± 1380 ± 1880 ± 20  LVEF (%)31 ± 730 ± 827 ± 627 ± 630 ± 830 ± 8Medication (%)  ACE inhibitor/ARB939397948789  Beta blocker959693927981  Diuretics808394948690*ACE* angiotensin converting enzyme*, ARB* angiotensin receptor blocker, *BMI* body mass index*, LVEF* left ventricular ejection fraction, *n.a.* not available*, NYHA* New York Heart Association, classification of heart failure

Discussion {#Sec11}
==========

Several recent randomized controlled trials (RCTs), including TIM-HF \[[@CR7], [@CR16]\] and INH \[[@CR14]\], have proven the positive clinical effects of home telemonitoring on several groups of patients diagnosed with CHF. The meta-analyses of Clark et al. \[[@CR4]\], Klersy et al. \[[@CR5]\] and Inglis et al. \[[@CR6]\] also showed its potential to improve several clinical outcomes such as quality of life. However, many results were not statistically significant mostly due to the fact that effects were too small despite adequately sized studies.

Another meta-analysis by Klersy et al. \[[@CR10]\] focused on the economic impact of remote patient monitoring. It showed that management of HF patients by remote monitoring is cost-saving due to a substantial reduction in health care resource utilization, mostly driven by a reduction in the number of HF hospitalizations. However, cost data in this meta-analysis was estimated using 3 diagnosis-related group reimbursements (minimum, median, maximum over countries) and 3 different incidence rates and their lower and upper 95 % CI (confidence interval). These facts reflect the requirement for additional study-derived and reliable evidence based on originally obtained cost data unlike previously negotiated prices.

In CardioBBEAT, the follow-up care of patients was more diverse than expected: the number of participating practices was higher whereas the number of patients per practice was lower than expected, resulting in an incomplete use of the random blocks implemented in the eCRF and slightly unequal sample sizes between the random groups. However, slight differences in group sizes are of no concern with respect to unbiasedness of results.

At first glance, an imbalance in baseline variables stands out. But, even with perfect randomization the expected number of statistically significant differences between baseline variables is 5 % or 2.45 of the 49 baseline comparisons in Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}, on average. In case of independence of the baseline variables, the observed number of significances will thus follow a binomial distribution with *p* = 0.05. In CardioBBEAT, 4 out of 49 baseline comparisons (8.2 %) were significant. In case of independence, 4 or more significant comparisons would occur in 23 % of the cases even in perfect randomization. The observed baseline differences could thus well be a play of chance. However, NYHA functional class, peripheral edema, heart rhythm, and renal dysfunction were clinically highly relevant variables that might bias the conclusions even if evoked by chance. Therefore, the statistical analysis plan was extended to include adjusted analyses with respect to the baseline imbalances.

Conclusions {#Sec12}
===========

CardioBBEAT is a RCT that adds a comprehensive cost assessment to the clinical component of the study including actual costs generated by patients, health services and health products. The corresponding data have been obtained directly from patients' health insurances including statutory sickness funds and private insurances. This will provide more reliable information about the cost-effectiveness of home telemonitoring in CHF patients based on the actual health care setting. CardioBBEAT may also be able to differentiate between particular sub-groups (gender-specific, NYHA-specific, urban/rural, diabetes mellitus) while analyzing the effectiveness of the intervention. The expectation is that important patient groups, which are better suited for the input of telemedicine with regard to the clinical and/or economic outcome, can be identified. The study results, reflecting a guideline-compliant, highly accurate treatment of the whole CardioBBEAT study population shown above, will significantly contribute to the existing data basis on home telemonitoring in CHF. Therefore, it adds to informed political and economic decision-making within the specific context of the German Health Care System.
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ACE

:   angiotensin converting enzyme

AE

:   adverse event

AHA

:   American Heart Association, staging of heart failure

ARB

:   angiotensin receptor blocker

BMI

:   body mass index

CHF

:   chronic heart failure

CI

:   confidence interval

CM

:   cardiomyopathy

COPD

:   chronic obstructive pulmonary disease

CRT-D

:   cardiac resynchronization therapy combined with defibrillation

DSL

:   Digital Subscriber Line (broadband connection)

ECG

:   electrocardiogram

eCRF

:   electronic Case Report Form

ESC

:   European Society of Cardiology

GFR

:   glomerular filtration rate

GP

:   general practitioner

HF

:   heart failure

ICD

:   implantable cardioverter defibrillator

ICER

:   Incremental Cost-Effectiveness Ratio

INH

:   Interdisciplinary Network for Heart failure study

KCCQ

:   Kansas City Cardiomyopathy Questionnaire with 23 items for measuring disease-specific domains in CHF

LBBB

:   left bundle branch block

LVEDD

:   left ventricular end-diastolic dimension

LVEF

:   left ventricular ejection fraction

MR

:   mineralocorticoid receptor

MWD

:   minute walking distance

n.a.

:   not available

NYHA

:   New York Heart Association, classification of heart failure

PAD

:   peripheral arterial disease

RBBB

:   right bundle branch block

RCT

:   randomized controlled trial

SAE

:   serious adverse event

SF-36v2

:   short form health survey with 36 questions using norm-based scoring

TELE-HF

:   Telemonitoring in patients with Heart Failure trial

TIA

:   transient ischemic attack

TIM-HF

:   Telemedical Interventional Management in Heart Failure trial

UMTS

:   Universal Mobile Telecommunications System (mobile cellular system)

WHO-5

:   World Health Organization Five, well-being index
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